Evidence map›Paper›PMID 33527181›Full record

ArticleAnalytical and bioanalytical chemistry2021

"Force iteration molecular designing" strategy for the systematic characterization and discovery of new protostane triterpenoids from Alisma Rhizoma by UHPLC/LTQ-Orbitrap-MS.

Jianqing Zhang, Qinghao Jin, Wenyong Wu, Xu Jin, Yaling An, Chen Liu, Wenlong Wei, Zhenwei Li, Changliang Yao, Shuai Yao and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Analytical and bioanalytical chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
3.0field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Jianqing Zhang *Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Haike Road #501, Shanghai, 201203, China.
Qinghao Jin *Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Haike Road #501, Shanghai, 201203, China.
Wenyong WuShanghai Institute of Materia Medica, Chinese Academy of Sciences, Haike Road #501, Shanghai, 201203, China.
Xu JinShanghai Institute of Materia Medica, Chinese Academy of Sciences, Haike Road #501, Shanghai, 201203, China.
Yaling AnShanghai Institute of Materia Medica, Chinese Academy of Sciences, Haike Road #501, Shanghai, 201203, China.
Chen LiuShanghai Institute of Materia Medica, Chinese Academy of Sciences, Haike Road #501, Shanghai, 201203, China.
Wenlong WeiShanghai Institute of Materia Medica, Chinese Academy of Sciences, Haike Road #501, Shanghai, 201203, China.
Zhenwei LiShanghai Institute of Materia Medica, Chinese Academy of Sciences, Haike Road #501, Shanghai, 201203, China.
Changliang YaoShanghai Institute of Materia Medica, Chinese Academy of Sciences, Haike Road #501, Shanghai, 201203, China.
Shuai YaoShanghai Institute of Materia Medica, Chinese Academy of Sciences, Haike Road #501, Shanghai, 201203, China.
Yong HuangShanghai Institute of Materia Medica, Chinese Academy of Sciences, Haike Road #501, Shanghai, 201203, China.
Hua QuShanghai Institute of Materia Medica, Chinese Academy of Sciences, Haike Road #501, Shanghai, 201203, China.
Jingyuan SongInstitute of Medicinal Plant Development, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100193, China.
Wanying WuShanghai Institute of Materia Medica, Chinese Academy of Sciences, Haike Road #501, Shanghai, 201203, China.
De-An GuoShanghai Institute of Materia Medica, Chinese Academy of Sciences, Haike Road #501, Shanghai, 201203, China. daguo@simm.ac.cn.
Shanghai Institute of Materia Medica · CNChinese Academy of Sciences · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNShenyang Pharmaceutical University · CN

Funding

National Key R&D Program of China 2019YFC1711000National Natural Science Foundation of China 81530095
6 · The paper itself

Abstract

Comprehensive analysis and identification of chemical components are of great significance for evaluating the efficacy and safety of herbal medicines, as well as for drug exploitation and development. Here we developed a "force iteration molecular designing" strategy, by combing a database-based in-house software for a precursor ion list (PIL) and PIL-triggered collision-induced dissociation-MS

Indexed as

AlismaChemistry Techniques, AnalyticalChromatography, High Pressure LiquidDrugs, Chinese HerbalIonsMagnetic Resonance SpectroscopyMass SpectrometryPlants, MedicinalReproducibility of ResultsSoftwareTriterpenesDrugs, Chinese HerbalIonsTriterpenesAlisma RhizomaForce iteration molecular designingProtostane triterpenoidsUHPLC/LTQ-Orbitrap-MS

Identifiers

PMID33527181
OpenAlexW3128598117

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.